Currently available strategies targeting Bcl-2 proteins in multiple myeloma have shown a benefit limited to patients with t(11;14) myeloma in the case of venetoclax and studies targeting both Bcl-2 and Mcl-1 have been fraught with cardiovascular toxicity. The gene discussed is BCL2; the disease is plasma cell myeloma.